Core Viewpoint - Novo Nordisk reported strong financial results for Q2, driven by significant growth in its product portfolio, particularly in diabetes and obesity care products [1][2]. Financial Performance - Q2 sales reached 76.857 billion DKK, a 13% year-over-year increase, and an 18% increase when adjusted for constant exchange rates (CER) [1]. - Operating profit for Q2 was 33.449 billion DKK, up 29% year-over-year, with a 40% increase on a CER basis [1]. - Net profit for Q2 was 26.503 billion DKK, reflecting a 32% year-over-year growth [1]. - For the first half of 2025, sales totaled 154.944 billion DKK, a 16% increase year-over-year, with a 18% increase on a CER basis [1]. Product Performance - The growth in global sales was attributed to the performance of the product portfolio, with GLP-1 diabetes drugs increasing by 8%, obesity care products by 53%, insulin by 5%, and rare disease drugs by 28% [2]. - Sales in the diabetes and obesity care segment for the first half of the year grew by 16%, reaching 145.4 billion DKK, with obesity care sales increasing by 56% to 38.8 billion DKK [2]. - Key products include Ozempic, with sales of 64.520 billion DKK (up 15%), Rybelsus at 11.348 billion DKK (up 5%), and Wegovy at 36.888 billion DKK (up 78%) [2]. Research and Development - Novo Nordisk is advancing the development of Amycretin for weight management and has initiated the REDEFINE11 study to explore the efficacy and safety of CagriSema [3]. - The company has submitted an application to EU regulators for a higher dose of semaglutide (7.2mg) [3]. - For the fiscal year 2025, the company anticipates sales growth of 8-14% and operating profit growth of 10-16% on a CER basis [3].